Thursday, March 16, 2017 8:44:34 AM
METHODS RELATED TO BIOLOGICS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"
[0030] Detailed, high resolution, physiochemical and/or structural information about Actemra.RTM. (e.g., related to the presence of signature glycan species or quantitative analyses ascribing site-specificity for backbone modifications) can be used in the manufacture of products that qualify as tocilizumab, e.g., that are interchangeable versions of Actemra.RTM.. Such information is also useful in monitoring product changes and controlling structural drift that may occur as a result of manufacturing changes. One exemplary report states that "[t]he size and complexity of . . . therapeutic proteins make the production of an exact replica almost impossible; therefore, there are no true generic forms of these proteins . . . . Verification of the similarity of biosimilars to innovator medicines remains a key challenge." (Hincal et al "An Introduction To Safety Issues In Biosimilars/Follow-On Biopharmaceuticals", J. Med. CBR Def, 7:1-18, (2009)). This disclosure provides, in part, methods and compositions sufficient to make and test products that qualify as tocilizumab, e.g., that are interchangeable versions of Actemra.RTM.. “
Boing X 2
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM